Table 2: Dosages of the chemotherapy.
# |
Underlying disease |
Dosage melphalan |
Dosage cytarabine |
Intrathecal chemotherapy |
Additional drugs |
1 |
cALL |
1 × 40 mg/m2 |
4 × 1 g/m2 |
Cytarabine 30 mg |
Anti CD19 antibody 20 mg/m2 |
2 |
pro-B-ALL |
1 × 60 mg/m2 |
4 × 1 g/m2 |
Cytarabine 20 mg, Prednisolone 6 mg |
|
3 |
Mixed phenotype AL |
2 × 60 mg/m²* |
2 × 1 g/m2 |
|
|
4 |
AML M2 |
2 × 33 mg/m2 |
4 × 1 g/m2 |
|
|
5 |
ALL |
1 × 20 mg/m²** |
10 × 100 mg/m²** |
Cytarabine 30 mg, Prednisolone 10 mg |
|
6 |
pro-B-ALL |
1 × 40 mg/m2 |
4 × 1 g/m2 |
Cytarabine 20 mg, Prednisolone 6 mg |
|
7 |
T-lymphoblastic lymphoma |
1 × 40 mg/m2 |
2 × 1 g/m2 |
|
Daratumomab 16 mg/kg |
8 |
AML M2 Auer |
1 × 40 mg/m2 |
5 × 100 mg/m2** |
|
Venetoclax 100 mg and 200 mg |
*High dosage because of a very aggressive form of AML as underlying disease; **Low dosage because of high cumulative toxicity prior to melphalan/cytarabine. ALL: Acute Lymphoblastic Leukemia; AML: Acute Myeloid Leukemia